Lovo works for
any manufacturing process.
Lovo can automate preparation for magnetic selections, simplifying and expediting day 0 processing. With Lovo 3.0 software, you have the option to incorporate mid-procedure, timed incubations in your protocol design.
| Measure | Result | |
|---|---|---|
| Source Products | Collections | n=5 |
| Volume | 163.3 ± 28.5 mL | |
| Total Nucleated Cells (TNC) | 10.9 ± 3.4 x 109 | |
| Platelet Count | 4.46 ± 0.92 x 10 11 | |
| Processing Time | Automated Processing Time (With incubation) | 58 minutes |
| Max Processing Time | 61 minutes | |
Source: LOVO 2.X Blood Run Protocol Report: 223-DER-048957 – Data on file at Fresenius Kabi USA.
| Measure | Result | |
|---|---|---|
| 2 wash cycles to remove platelets and prepare for incubation | Platelet Depletion | 98.4 ± 1.0% |
| Targeted Pre-Incubation Volume | 100 mL | |
| Actual Pre-Incubation Volume | 100.6 ± 1.2 mL | |
| Full Procedure | TNC recovery | 97.2 ± 3.7% |
| TNC Viability | 96.3 ± 1.4% | |
Source: LOVO 2.X Blood Run Protocol Report: 223-DER-048957 – Data on file at Fresenius Kabi USA.
Quickly and easily remove platelets from leukapheresis products while recovering TNCs and maintaining cell viability.
| Measure | Result | |
|---|---|---|
| Collections (5L) |
Fenwal Amicus | n=6 |
| Spectra Optia | n=8 | |
| Source | Volume | 90.8 ± 10.2 ml |
| TNC | 4.7 ± 1.8 x 109 | |
| Final Product |
TNC Recovery | 98.6% |
| TNC Viability | 97.5% | |
| Target Final Volume | 95 mL | |
| Actual Final Volume | 95.3 ± 0.6 mL | |
| Processing Time | Average | 11:01 min |
| Maximum | 11:29 min | |
Source: LOVO 2.X Product Quality Test Results Design Review: 223-DER-048958 – Data on file at Fresenius Kabi USA.
Pre/Post Lovo Wash Platelet Count & Depletion
Source: LOVO 2.X Product Quality Test Results Design Review: 223-DER-048958 – Data on file at Fresenius Kabi USA.
Quickly and easily wash and concentrate up to 22L of cultured cells in one automated and functionally closed system.
Study objective
Goals
| Cell Type | Lovo Fresenius Kabi |
CS5+ Haemonetics |
Manual |
|---|---|---|---|
| Recovery (%) | 93 ± 4 | 87 ± 3 | 91 ± 4 |
| Processing Time (min) | 30 ± 1 | 25 ± 4 | 61 ± 11 |
| Washout Efficiency (%) | 99.5 | 99.9 | 99.8 |
| Final Volume (mL) | 150 ± 1 | 153 ± 3 | 151 ± 6 |
| Cellular CQAs1 | comparable | ||
| Automated | ✓ | ± | x |
| Functionally Closed | ✓ | ± | x |
1 Critical Quality Attributes (CQAs) Measured: viability assessment, phenotype, cell functionality, ancillary materials.
Source: Lovo New Membrane Cultured Cell Testing Results: 223-DER-066723 – Data on file at Fresenius Kabi USA.
Wash cryopreserved products and resuspend cells in your preferred buffer or culture media.
| Measure | Lovo 2.0 (three-cycle) |
|---|---|
| Number of Runs | 6 |
| PCV% | 8.4% (6.9 - 11.4) |
| Viable CD34+ Cell Recovery | 84% (61 - 93) |
| CD34+ Cell Viability | 92% (81 - 94) |
| DMSO Elimination | 97% (97 - 98) |
| Total Processing Time | 62 min |
† Data is expressed as median and (IQR)
Source: B.Mfarrej, et al. Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, Volume 19, Issue 12, 1501-1508.
3-Cycle Wash1
Post Thaw Recovery
Source: B.Mfarrej, et al. Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy, Volume 19, Issue 12, 1501-1508.
Stay Informed.
Sign up below to receive the latest Lovo news and updates.
See Us In Action.
Come see what Lovo’s all about. We’ll walk you through the features and arrange a demo.
6th Annual TIL Therapies Summit
October 18, 2024
Boston, MA
ESGCT Annual Congress
October 22-25, 2024
La Nuvola, Rome, Italy
Society for Immunotherapy of Cancer (sitc)
November 6-10, 2024
Houston, TX
The Lovo Cell Processing System is for laboratory use only and may not be used for direct transfusion. Appropriate regulatory clearance is required by the user for clinical use.
For applications requiring regulatory clearance or approval, Users may request the required Lovo technical documentation from Fresenius Kabi to support their submissions.
Refer to the Lovo Cell Processing System Operator’s Manual for a complete list of warnings and precautions associated with the use these products.
References
1-4Data on File at Fresenius Kabi USA